Highest-materiality recent filing
Centene CFO Drew Asher to retire; Chris Neczypor named successor effective Jan 1, 2027
Asher steps down as CFO Dec 31, 2026, stays as Strategic Advisor through 2027.
Centene Q2 GAAP EPS $2.19, adj. EPS $2.51; raises 2026 guidance; board changes
Q2 GAAP diluted EPS $2.19, adjusted diluted EPS $2.51; total revenues $53.6B, premium & service revenues $44.4B.
Centene Q1 2026 GAAP EPS $3.11, Adjusted EPS $3.37; Raises 2026 Guidance
GAAP diluted EPS $3.11, adjusted diluted EPS $3.37 (~$0.50 above expectations).
Centene reports FY 2025 GAAP loss of $13.53 per share; guides FY 2026 adj. EPS >$3.00
Full-year GAAP diluted loss per share $(13.53) includes $6.7B goodwill impairment; adjusted diluted EPS $2.08.
Centene Q3 GAAP loss $(13.50) from $6.7B impairment; adjusted EPS $0.50; raises FY guide to $2.00
GAAP diluted loss per share $(13.50) driven by $6.7B non-cash goodwill impairment; adjusted diluted EPS $0.50.
Centene Q2 2025: diluted loss per share $(0.51); HBR rises to 93.0%
GAAP diluted loss per share $(0.51); adjusted diluted loss per share $(0.16).
Centene withdraws 2025 guidance due to $1.8B risk adjustment hit
Withdraws 2025 GAAP and adjusted EPS guidance; preliminary $1.8B net risk adjustment revenue reduction (~$2.75 EPS impact).
Centene Q1 adjusted EPS $2.90 beats $2.26 YoY; raises FY revenue guidance by $6B
Adjusted diluted EPS of $2.90 vs $2.26 in Q1 2024 (+28%); GAAP EPS $2.63.
Centene Q4/FY2024: adj EPS $7.17 (+7% YoY), raises 2025 revenue guide by $4B
Full year 2024 adjusted diluted EPS $7.17, up 7% from $6.68; GAAP EPS $6.31.
Centene announces 2025 adj. EPS guidance >$7.25, 6% YoY growth; reaffirms 2024
2025 adj. diluted EPS guidance >$7.25; GAAP diluted EPS >$6.19.
Centene Q3 adjusted EPS $1.62, revenue $36.9B, reaffirms FY24 adjusted EPS guidance >$6.80
Adjusted diluted EPS of $1.62; GAAP EPS $1.36. Premium + service revenue $36.9B (+6% YoY).
Centene MA Star Ratings improve: 46% of members in 3.5+ star plans vs 23% prior year
CMS released 2025 Medicare Advantage Star Ratings on Oct 10, 2024; Centene's membership in plans rated 3.5+ stars rose to ~46% from ~23% year-over-year.
Centene Q2 2024 adjusted EPS $2.42 (+15% YoY); reaffirms FY adj. EPS floor >$6.80
Adjusted diluted EPS $2.42, up 15% from $2.10 in Q2 2023; GAAP diluted EPS $2.16.
Centene books $0.7B net risk adjustment gain; prelim Q2 adj. EPS $2.42
CMS final 2023 risk adjustment receivable $0.0B vs. Centene's $1.3B net payable recorded.
Centene reaffirms FY adj EPS >$6.80, adds $125M reserve for 2025 MA bids; Medicaid costs elevated
Reaffirmed FY2024 adjusted diluted EPS >$6.80 and consolidated health benefits ratio 87.3%-87.9%.
Centene Q1 adjusted EPS $2.26 beats; raises FY2024 guidance to >$6.80
GAAP diluted EPS $2.16; adjusted diluted EPS $2.26 (+7% YoY); premium & service revenues $36.3B (+4% YoY).
Centene posts FY2023 adjusted EPS $6.68, up 15%; raises 2024 revenue guidance $2.5B
FY2023 adjusted diluted EPS $6.68 (up 15% from $5.78); GAAP diluted EPS $4.95.
Centene guides 2024 adjusted EPS >$6.70, raises buyback by $4B
2024 adjusted diluted EPS guidance of greater than $6.70; GAAP diluted EPS greater than $5.61.
Centene appoints Susan Smith as COO effective Jan 1, 2024
Susan Smith, 48, joins from Humana where she spent 19 years, most recently as SVP of Clinical, Quality and Enterprise Solutions President.
Centene Q3 adjusted EPS $2.00, raises FY23 guidance to at least $6.60
GAAP diluted EPS $0.87; adjusted diluted EPS $2.00, up 53% YoY from $1.30.
Centene reports 73% of MA members in contracts with improved 2024 star scores; 87% at 3+ stars
Approximately 73% of membership in contracts with year-over-year unrounded score improvement.
Centene Q2 adjusted EPS $2.10 beats prior year; raises full-year guidance to at least $6.45
GAAP diluted EPS $1.92; adjusted diluted EPS $2.10 (+18% vs $1.77 in Q2 2022).
Effective June 19, 2026, the Board of Directors (the Board) of Centene Corporation (the Company) increased the size of the Board from 9 to 10 and elected Lauren Tyler to the Board to fill the resulting vacancy
On November 8, 2024, Kenneth J. Fasola, President of Centene Corporation (the "Company"), informed the Company that he intends to retire from the Company on July 1, 2025.
On September 25, 2024, Director Lori J. Robinson notified Centene Corporation (the “Company”) of her decision not to stand for re-election when her term expires at the Company’s 2025 Annual Meeting.
elected Thomas Greco to the Board to fill the resulting vacancy
James E. Murray has retired from the Company effective March 29, 2024.
On November 15, 2023, Centene Corporation (the “Company”) announced that Susan Smith, 48, will be appointed as the Company’s Chief Operating Officer, effective January 1, 2024.
On May 19, 2023, James E. Murray, Chief Operating Officer (“COO”), formally notified the Company of his plans to retire in 2024.
Brent Layton, the Company’s current President and Chief Operating Officer, will transition to the role of Senior Advisor to the Chief Executive Officer as a non-executive officer until his planned retirement on December 31, 2023.
announced that the Board of Directors of the Company had appointed Kenneth Fasola, 63, as President of the Company and James Murray, 69, as Executive Vice President, Chief Operating Officer of the Company effective as of December 14, 2022.
announced that the Board of Directors of the Company had appointed Kenneth Fasola, 63, as President of the Company and James Murray, 69, as Executive Vice President, Chief Operating Officer of the Company effective as of December 14, 2022.
On November 12, 2022, the board of directors (the “ Board ”) of Centene Corporation (the “ Company ”) elected Monte Ford to the Board
On April 11, 2022, Leslie Norwalk resigned, effective immediately, as a member of the board of the directors (the “Board”) of Centene Corporation (the “Company”).
Max materiality 0.85 · Median 0.50 · Most common event earnings